Corcept Therapeutics
CORT
224 hedge funds and large institutions have $1.51B invested in Corcept Therapeutics in 2020 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 73 increasing their positions, 67 reducing their positions, and 25 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
84% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 25
43% more capital invested
Capital invested by funds: $1.05B → $1.51B (+$456M)
14% more call options, than puts
Call options by funds: $12.4M | Put options by funds: $10.8M
10% more funds holding
Funds holding: 204 → 224 (+20)
1.06% more ownership
Funds ownership: 77.13% → 78.19% (+1.1%)
9% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 67
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.99M |
| 2 |
Renaissance Technologies
New York
|
+$8.67M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$5.22M |
| 4 |
Norges Bank
Oslo,
Norway
|
+$5.2M |
| 5 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
+$4.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$6.4M |
| 2 |
Morgan Stanley
New York
|
-$5.98M |
| 3 |
ISL
Ingalls & Snyder LLC
New York
|
-$5.68M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$4.1M |
| 5 |
Man Group
London,
United Kingdom
|
-$3.66M |
CORT Hedge Fund Activity: Q2 2020 in Review
224 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2020, worth a combined $1.51B — up 43% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new CORT positions and 25 closed out — a net gain of 21 holders — while 73 added to existing stakes and 67 trimmed.
The largest buyer was BlackRock, adding an estimated $8.99M. The largest seller was Marshall Wace, exiting entirely with an estimated $6.4M sold.
- 224 institutional investors held Corcept Therapeutics (CORT) as of Q2 2020, up from 204 in Q1 2020.
- Funds reported $1.51B of Corcept Therapeutics stock for Q2 2020, up 43% quarter-over-quarter.
- 46 funds opened new Corcept Therapeutics positions in Q2 2020 and 25 closed out, a net change of +21 holders.
- The largest Corcept Therapeutics buyer in Q2 2020 was BlackRock, an estimated $8.99M added.
- The largest Corcept Therapeutics seller in Q2 2020 was Marshall Wace, an estimated $6.4M sold.
Based on aggregated 13F filings for Q2 2020.